Pfizer Inc
NYSE: PFE
$25.77
-$0.40 (-1.5%)
Closing Price on November 26, 2024
PFE Articles
BioNTech is one of the leading companies in the race to a COVID-19 vaccine. With its shares up more than 160% year to date, it’s time to capitalize.
Published:
BioNTech and Pfizer are leading the pack of COVID-19 vaccine stocks as this collaboration came out with more positive news regarding their ongoing German Phase 1/2 study.
Published:
The number of COVID-19 cases continues to rise, which will only create more demand for coronavirus stocks. 24/7 Wall Street has picked out a few of the best and brightest that could still see a big...
Published:
Pfizer and BioNTech have progressed in their COVID-19 vaccine effort, according to the FDA. Two of the companies’ four coronavirus vaccine candidates received Fast Track Designation.
Published:
As of the most recently reported period, short sellers still favored Exxon, Pfizer and Microsoft above all other Dow stocks.
Published:
24/7 Wall St. has identified five defensive stocks that must greatly improve before they are deemed expensive or fully valued again.
Published:
Pfizer is among the current frontrunners for a COVID-19 vaccine, so why is its stock down 13% year to date? And why does one independent research firm say this stock could run much higher?
Published:
24/7 Wall Street has picked out a few of the best and brightest coronavirus stocks that could still see a big push as 2020 continues.
Published:
Pfizer and BioNTech have been collaborating to produce a messenger RNA based vaccine for the past few months, and this work is yielding promising results.
Published:
As of the most recently reported period, short sellers still favored Exxon, Pfizer and Microsoft above all other Dow stocks.
Published:
As of the most recently reported period, short sellers still favored Exxon, Pfizer and Microsoft above all other Dow stocks.
Published:
As of the most recently reported period, short sellers favored Exxon, Pfizer and Microsoft above all other Dow stocks.
Published:
As of the most recently reported period, short sellers favored Exxon, Pfizer and Microsoft above all other Dow stocks. The overall trend of shrinking short interest continued.
Published:
BioNTech and Pfizer stocks each made a handy gain on Monday after the companies announced the beginning of human trials for a COVID-19 vaccine.
Published:
Merck and Pfizer reported their most recent quarterly results before the opening bell Tuesday. Although markets appear to be recovering, investors were not thrilled about this quarter for these two...
Published: